Bury Jarosław, Szumiło Justyna, Dąbrowski Andrzej, Ciechański Aleksander, Śliwińska Justyna, Wallner Grzegorz
Department of General Surgery, Hospital of Ministry of Interior in Lublin.
Pol Przegl Chir. 2012 Jul;84(7):341-7. doi: 10.2478/v10035-012-0057-5.
Two molecules - vascular endothelial growth factor involved in new vessels formation and survivin - antiapoptotic protein, reported to be associated with worse prognosis in various malignancies have been chosen for the study. Both are potential target for novel therapies.
Was to determine the immunostaining of VEGF and survivin in gastric carcinoma and to analyse their relationship to the selected clinicopathological features and survival.
Formalin-fixed, paraffin-embedded sections from 41 gastric adenocarcinomas were used for immunohistochemical reaction with monoclonal antibodies against vascular endothelial growth factor and survivin. The results were compared with selected clinicopathological features and survival.
Positive immunohistochemical reaction for vascular endothelial growth factor and survivin was revealed in 24 (58,53%) and 30 (73,17%), gastric carcinomas respectively. Vascular endothelial growth factor-negative gastric carcinomas were significantly more common in cases without metastases to regional lymph nodes and distant organs and in less advanced cases. Similar, distant metastases were also statistically less common in survivin-negative carcinomas. The differences in immunohistochemical reactions for survivin between less and more advanced cases almost reach statistical significance. The only factors significantly influenced 1, 2 and 3-year survival were vascular endothelial growth factor and survivin status. Statistically significant higher percentage of survival was noted in patients with vascular endothelial growth factor- and survivin-negative tumors.
It seems that vascular endothelial growth factor and survivin play role in local invasion and spread of gastric adenocarcinoma and negatively influences survival. However, further studies are required to assess their true usefulness in the clinical practice.
本研究选取了两种分子——参与新血管形成的血管内皮生长因子和抗凋亡蛋白生存素,据报道它们在多种恶性肿瘤中与较差的预后相关。两者都是新型疗法的潜在靶点。
确定血管内皮生长因子(VEGF)和生存素在胃癌中的免疫染色情况,并分析它们与所选临床病理特征及生存率的关系。
采用41例胃腺癌的福尔马林固定、石蜡包埋切片,用抗血管内皮生长因子和生存素的单克隆抗体进行免疫组化反应。将结果与所选临床病理特征及生存率进行比较。
分别在24例(58.53%)和30例(73.17%)胃癌中发现血管内皮生长因子和生存素的免疫组化反应呈阳性。血管内皮生长因子阴性的胃癌在无区域淋巴结和远处器官转移的病例以及病情较轻的病例中更为常见。类似地,生存素阴性癌的远处转移在统计学上也较少见。病情较轻和较重病例之间生存素免疫组化反应的差异几乎达到统计学意义。唯一显著影响1年、2年和3年生存率的因素是血管内皮生长因子和生存素状态。血管内皮生长因子和生存素阴性肿瘤患者的生存率在统计学上显著更高。
血管内皮生长因子和生存素似乎在胃腺癌的局部侵袭和扩散中起作用,并对生存率产生负面影响。然而,需要进一步研究以评估它们在临床实践中的真正实用性。